GLP-1 and Blindness: What We Know About NAION and Vision Loss (October 2026)

01 · The core answer

Does GLP-1 cause blindness? The honest short answer

Blindness is not listed as a side effect in the UK Mounjaro patient leaflet, but a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION) is being investigated in people who use GLP-1 medicines. NAION happens when blood flow to the optic nerve drops. It typically causes sudden, painless loss of vision in one eye, and the damage can be permanent. That is why the topic deserves a serious, calm answer rather than either panic or dismissal.

Most discussion concerns partial or sudden loss of vision in one eye, not total loss of sight in both. The absolute risk is described as very low, and it is still under active study.

For the wider discussion, see our guide on whether GLP-1 can cause blindness.

02 · Is this relevant to me?

Is this relevant to you?

It is most relevant if you already have an eye condition, have noticed any change in your vision, or have diabetes with eye complications. Mounjaro is not suitable for everyone, and your prescriber takes extra care, or may recommend against treatment, if you have a history of diabetic retinopathy, among other conditions.¹³ This is why the consultation asks about your full medical history and medicine list.

If you have no eye problems, the practical position is simple. You do not need to stop an effective, licensed treatment because of a headline. You do need to know the warning signs, keep your routine eye tests, and tell a clinician quickly if your vision changes suddenly. Weighing that against the established benefits of treatment is a conversation to have with your prescriber, using your own history rather than an internet average.

If you are worried about a symptom right now, get medical help straight away: contact NHS 111, an urgent eye service or emergency services depending on how sudden and severe it is.

03 · What to do next

What to do next

Your next step depends on where you are. If you are already on treatment and your vision changes suddenly, get medical help straight away and tell the clinician which medicine you take. If you are ready to look at treatment, the free consultation is the pathway: your answers are reviewed by a GPhC-registered prescriber, and unsuitable orders are refunded automatically.

If you simply want to understand weight-loss medicine more broadly, our weight loss clinic hub brings the main guides together. Whatever you decide, a regular eye test with an optometrist is sensible for anyone, and particularly for anyone with diabetes.

Related guides: Agonisti glp 1 and Ozempil glp-1 and Wat is glp-1.

Related guide: Trapezoid glp 1.

04 · What NAION is

What NAION is and why it gets called an eye stroke

NAION stands for non-arteritic anterior ischaemic optic neuropathy. In plain terms, it is damage to the front of the optic nerve caused by a reduced blood supply. The optic nerve carries visual signals from the eye to the brain, so when it is starved of blood the result is a sudden drop in vision. People often describe it as painless, noticed on waking or at some point during the day, usually affecting one eye.

It is called an "eye stroke" because the mechanism resembles a stroke elsewhere in the body: a part of the nervous system loses its blood flow. The comparison is a description, not a claim that it is the same disease as a brain stroke. NAION is a recognised condition in its own right and was known long before modern weight-loss medicines existed. It affects people with and without any medicine exposure.

This matters for how to read the headlines. NAION has a background rate in the general population, and certain people are more prone to it, including people with vascular risk factors. When researchers ask whether a medicine is linked to NAION, they are asking whether people taking it develop the condition more often than comparable people who are not. That is a statistical question about a rare event, and rare events are hard to study. Results can differ depending on the group studied, how long they were followed and how the diagnosis was recorded.

It is also worth separating NAION from other causes of sudden vision problems, which are far more common. Migraine auras, dry eyes, blood-sugar swings, dehydration, retinal problems and ordinary eyestrain can all cause visual disturbance.

In short: NAION is a real, rare and serious condition; it is not the same as gradual age-related sight loss; and the question is whether GLP-1 medicines nudge its likelihood upward in a very small number of people.

05 · What the studies say

What the studies say about NAION and GLP-1

Most of the published work looks back at health records and compares people who were prescribed a GLP-1 medicine with people who were not, then counts new cases of NAION. These studies can suggest an association, but they cannot prove cause. People prescribed these medicines often have diabetes, obesity, high blood pressure or sleep apnoea, and those are themselves associated with NAION. Untangling the medicine from the underlying conditions is difficult, and different studies, using different populations, have not all reached the same conclusion.

The studies also mostly concern semaglutide, the active ingredient in Ozempic and Wegovy, because it has been prescribed to very large numbers of people for longer. Findings about one medicine do not automatically transfer to another, even within the same class. Tirzepatide is newer and acts on two receptors rather than one, as described in the product information.¹

The absolute risk is described as very low, so most people taking these medicines will never experience this condition.

If you want the primary evidence, the SmPC and patient information leaflet for your specific medicine are the authoritative, regularly updated sources. They reflect what regulators have concluded, which is more reliable than a social media thread or a law-firm advertisement.

06 · Mounjaro and eye risk

Does Mounjaro cause eye blindness?

Blindness is not listed as a side effect in the UK patient leaflet. The honest position on NAION is that it is being investigated across the GLP-1 class, and that you should read the current product information rather than rely on any summary. The electronic medicines compendium entries for the KwikPen carry the full side-effect list, and the patient information leaflet gives the version written for you.¹¹³

If you notice any new symptom while using Mounjaro, including changes in vision, talk to your prescriber. The MHRA Yellow Card scheme exists for exactly this purpose, and anyone can use it, including patients, not only clinicians.¹⁹ A suspected side effect reported once tells regulators little; many reports across many people are how signals emerge.

It also helps to know that Mounjaro is a different molecule from semaglutide. The mechanism described in the product information is that tirzepatide activates both GIP and GLP-1 receptors, which help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ That difference is interesting, but nobody should treat it as proof of a different eye-safety profile.

The takeaway for a Mounjaro user is balanced: no established blindness effect, an open research question about a rare optic-nerve condition, a clear list of warning signs, and a clear route for reporting. Your prescriber can tell you if anything in your history changes how the benefits and risks balance for you.

07 · Who should take extra care

Who should take extra care with their eyes

The people who should think hardest about eye health before starting a GLP-1 medicine are those with existing eye disease, especially diabetic retinopathy. Mounjaro is not suitable for everyone. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹³ Diabetic retinopathy appears in that list for a reason: your eyes need individual attention, and decisions should be made with full information.

That is why the consultation asks for your complete medical history and medicine list, and why we ask you to be thorough rather than quick. Sharing everything is how the prescriber can weigh benefits and risks in your specific case. Please mention any previous episode of sudden vision loss, any diagnosis from an eye clinic, any laser or injection treatment to the eye, and any eye medication you use.

Beyond the formal list, some general points are sensible. People who have diabetes should keep attending their routine diabetic eye screening; treatment for weight or blood sugar does not replace it. People with other vascular risk factors should keep those managed with their GP. And anyone who has previously had NAION in one eye should discuss this plainly with a clinician before starting any new medicine, because the condition can in principle affect the other eye.

If you take insulin or a sulfonylurea alongside Mounjaro, low blood sugar is something to watch for, with shakiness, sweating and confusion as warning signs; your prescriber may need to adjust those medicines.¹ Low blood sugar can itself cause blurred or disturbed vision, which is another reason to report visual symptoms promptly rather than assume the cause.

Finally, be honest with yourself about symptoms you have been ignoring. If you have had unexplained visual blackouts, shimmering, a shadow over part of your vision or sudden loss of sight in one eye, get medical help straight away, and tell your prescriber before starting treatment. A prescriber can only weigh a risk they know about.

08 · Warning signs and urgent help

Warning signs: sudden vision loss, blackouts and eye stroke symptoms

Sudden loss of vision in one eye, or a shadow or dark area that appears quickly and does not clear, needs medical help straight away. Do not wait to see whether it improves, and do not wait for your next scheduled review. The reason is simple: some causes of sudden vision loss are time-critical, and only an in-person examination can tell them apart.

Common causes of sudden vision loss include problems with the blood supply to the eye or optic nerve, retinal detachment, bleeding inside the eye, inflammation, migraine and certain brain events. This list is deliberately broad, because you cannot tell the cause from the symptom. That is the point of urgent assessment.

Vision blackouts and seeing nothing for a few seconds have many possible explanations, from standing up quickly and a brief drop in blood pressure to migraine and, less commonly, temporary reductions in blood flow. If the episodes are repeated, affect one eye, or come with weakness, speech trouble or facial drooping, treat them as an emergency. A single brief episode that you cannot explain still needs prompt assessment: contact NHS 111, and get medical help straight away if it does not clear.

Early warning signs of an eye stroke or a transient eye attack can include a temporary curtain or shade across one eye that then clears. Anything that looks like this needs medical help straight away, because it can precede a permanent event. Some stroke warning signs outside the eye, such as sudden facial droop, arm weakness or slurred speech, mean you should call emergency services immediately.

Can a doctor tell by looking in your eyes? An eye examination can reveal changes at the back of the eye, including swelling of the optic nerve head, which helps clinicians assess what is happening. It is one part of a wider assessment, not a stand-alone test, and it is done by trained professionals rather than remotely.

Keep a few practical points in mind. Note which eye is affected, whether covering each eye in turn changes what you see, and when it started. Bring your medicine list, including that you use a GLP-1 medicine, so the clinician has it to hand. Severe, persistent stomach pain that may spread to the back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of the skin or eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing need immediate medical help: get medical help straight away.¹

Dehydration from vomiting or diarrhoea can also make you feel faint and affect how well you see, so keep fluids up and get medical help straight away if you cannot keep fluids down.¹

09 · Benefits and risks in balance

Weighing the benefits against a rare risk

A sensible decision weighs a rare, still-under-study eye risk against the established benefits of treating excess weight. This is not a reason to dismiss the risk.

Mounjaro is licensed in the UK for weight management in adults and for type 2 diabetes. It is used alongside a reduced-calorie diet and increased physical activity.¹ In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, and individual results vary.

Beyond the scales, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels. These are trial-average secondary outcomes, not promises, but they are why prescribers talk about weight management as health management rather than appearance.²

Why does this matter for an eye question? Because the conditions that treatment aims to improve, such as high blood pressure and raised blood sugar, are themselves harmful to eyes and blood vessels over the long term. A risk that is rare and uncertain sits alongside benefits that are measured and substantial for people who meet the criteria. Neither side cancels the other out; both belong in your decision.

We would not use that argument to wave away a symptom, and we would not use a scary headline to talk someone out of a treatment they have good reason to use. The right approach is individual: your history, your eye health, your reasons for treatment, and a prescriber who has all of it. If you have had previous sudden vision loss, or have retinopathy, that conversation matters even more, and the answer may be that treatment is not right for you.

Treatment also does not have to be permanent. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system; there is no way to speed this up, and nothing needs doing while it clears.¹ If you and your prescriber decide to stop because of a concern, that route is open.

10 · Other GLP-1 medicines

Does the concern apply to Wegovy and other GLP-1 medicines?

The eye question is a class-wide topic, not a Mounjaro-only one, and most of the published attention has focused on semaglutide. Semaglutide is the ingredient in Wegovy and Ozempic. Because it has been used by very large numbers of people, it has been studied the most, and that is also why headlines tend to mention it.

Liraglutide, sold as Saxenda and in some other products, is a daily injection supplied at 6mg/ml, unlike once-weekly Mounjaro and Wegovy.

Where a head-to-head comparison genuinely exists, it is for weight loss, not for eye outcomes. In SURMOUNT-5, 751 adults took tirzepatide or semaglutide 2.4mg for 72 weeks. At least 10% of body weight was lost by 81.6% on tirzepatide vs 60.5% on semaglutide; at least 15% by 64.6% vs 40.1%; at least 20% by 48.4% vs 27.3%; at least 25% by 31.6% vs 16.1%. Average loss was 22.8 kg vs 15.0 kg.¹⁵ That tells you about weight loss, not about eye safety, and it would be wrong to use it to say one medicine is safer for eyes.

If you are weighing up treatments, the Wegovy pen and the Mounjaro pen are both licensed options, and your prescriber can discuss which suits you. For any medicine, the same advice applies: read the current product information, report new symptoms, and treat sudden vision loss as an emergency.

A fair summary is that the eye question is open for the class, that no medicine in it should be described as risk-free, and that you are best served by a clinician who knows your history rather than by a general claim in either direction.

11 · Reporting and aftercare

Reporting symptoms, aftercare and NHS access

If you think a medicine has caused a symptom, report it through the MHRA Yellow Card scheme, and tell your prescriber. Yellow Card reports from patients and clinicians are how UK regulators pick up rare problems that trials are too small to find.¹⁹ You do not need proof that the medicine caused the problem. A suspicion is enough, and a report is not an accusation.

When you order with us, the process is built around making that kind of conversation easy. The online consultation is free and reviewed by a GPhC-registered prescriber, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Aftercare includes ongoing monthly reviews, dose titration and follow-up assessments by the prescribing team, plus side-effect support. Repeat orders re-check suitability, and nothing is shipped automatically, so there is a natural point to report a new symptom or change in health.

Our support team is available Monday to Friday, 9am to 5pm, by email at support@everydaymeds.co.uk, through the account portal chat or by phone on 0333 207 0413. Please note that support is not an emergency service. For sudden vision loss, get medical help straight away: use NHS 111, an urgent eye service or emergency services.

We supply genuine Mounjaro KwikPens through official LillyDirect supply, sourced directly from Eli Lilly, and we are registered with the GPhC (9012878). That matters here because a safety conversation is only meaningful if the product is genuine.

On the NHS route, Mounjaro is available, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions). Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁴ Whichever route you use, tell the prescriber about any eye history.

If you want a record to bring to appointments, the free GLPTrackr companion app can help you note when symptoms began relative to your doses, which makes any conversation with a clinician more precise.